KALRAY
Kalray (Euronext Growth Paris: ALKAL), a leader in hardware and software technologies dedicated to data management and data intensive processing from cloud to edge, today announced a strategic collaboration with Arm to deliver ultra-high performance data processing and AI capabilities across a broad set of applications, leveraging Kalray’s industry leading data processing unit (DPU) technology and Arm’s robust partner ecosystem.
The ever-increasing demand for advanced data processing and AI capabilities has become a cornerstone of modern applications, ranging from storage and networking appliances to data center servers and edge computing, such as smart vision systems or telecom solutions.
This diverse application spectrum requires innovative solutions that can manage increasing data and processing requirements while delivering peak performance and high levels of power and cost efficiency. The combination of Kalray’s advanced AI and data processing acceleration capabilities paired with the broad Arm partner ecosystem will make high performance solutions for hardware and software developers across global enterprises more accessible.
In practical terms, this collaboration translates into Kalray integrating Arm® Neoverse™ Coherent Mesh Network (CMN) interconnect technology into Kalray’s next generation data processing and AI accelerator chiplet (code named “Dolomites”). This will enable the connection of Kalray’s DPU to Arm-based chiplets1 using the Arm CMN interconnect, delivered in the same package. It’s an innovative approach that optimizes flexibility, performance, power consumption, and cost efficiency; and it’s aimed at opening new horizons for a wide ecosystem of software developers, enabling them to leverage Kalray’s advanced processor capabilities to drive innovation across multitudes of applications.
“We couldn’t be more thrilled to collaborate with Arm and to bring the unique AI and data intensive processing capabilities offered by our DPU technology to the global Arm ecosystem,” said Eric Baissus, Kalray CEO. “This is a visionary step towards shaping the future of AI processing, making it more accessible, efficient, and powerful for a wider range of applications."
“AI is becoming integral to the entire compute infrastructure, driving an insatiable demand for more data and more computing power,” said Dermot O’Driscoll, vice president of product solutions, Infrastructure Line of Business, Arm. “By leveraging Arm’s CMN interconnect technology, Kalray is making its data acceleration solutions accessible across Arm’s global ecosystem and we look forward to this collaboration sparking new and impactful innovation for the era of AI.”
“This announcement maps to our expectation of increasing data processing solutions that address the expanding set of AI workloads,” said Howard Holton, chief technology officer, GigaOm. “The combination of Arm’s unique ecosystem and Kalray’s innovative DPU technology has the potential to bring the best of two worlds together at a time when the market has an insatiable appetite for data intensive processing.”
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented data processing unit (DPU) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, media & entertainment, life sciences, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
ABOUT ARM
Arm technology is building the future of computing. Its energy-efficient processor designs and software platforms have enabled advanced computing in more than 270 billion chips and its technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, Arm is enabling artificial intelligence to work everywhere, and in cybersecurity, it is delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
1 A chiplet is a discrete unpackaged die that can be assembled into a package with other chiplets and assembled into a single processor chip. This new approach enables the development of processors that combine multiple chiplets, offering gains in flexibility and efficiency compared to traditional approaches.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207386465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom